항암 및 항암보조제
Oncology Portal | News
Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting
Dose escalation of neratinib lowers the frequency of severe diarrhea and improves overall tolerability in patients with HER2-positive early stage breast cancer
Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
Neratinib efficacy evidenced in patients with EGFR exon 18-mutant non-small cell lung cancer and CNS involvement
Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting
Results show improved outcomes in overall survival in patients with HER2-positive early stage breast cancer who received &ge= 11 months of treatment with neratinib
https://pumabiotechnology.com/pr20201211_NALA.html
https://pumabiotechnology.com/pr20201209_ExteNET.html
https://pumabiotechnology.com/pr20201209_SUMMIT.html
https://pumabiotechnology.com/pr20201117.html
https://pumabiotechnology.com/pr20201105_SUMMIT.html
https://pumabiotechnology.com/docs/101520_NCCNORP_Puma_Neratinib.pdf
Copyright 2020 - BIXINK | Terms of Use | Contact
서울특별시 강남구 강남대로 292 6층 [06258]
6F, 292 Gangnam-daero, Gangnam-gu, Seoul 06258, Republic of Korea